title: The role of factor Xa inhibitors in venous thromboembolism treatment.
abstract: Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.
authors: Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
authors: Katherine P
authors: KP
authors: Cabral
authors: Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA.
authors: Jack E
authors: JE
authors: Ansell
mesh_terms: D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D065427:Factor Xa Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011728:Pyridones / Q000627:therapeutic use; D012307:Risk Factors; D000069552:Rivaroxaban; D013844:Thiazoles / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000097:blood / Q000188:drug therapy*
chemical_list: D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; C522181:apixaban; D000069552:Rivaroxaban; C552171:edoxaban
keywords: anti-Xa inhibitors; apixaban; edoxaban; rivaroxaban; venous thromboembolism